Research Paper Volume 8, Issue 12 pp 3520—3534
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer
Figure 5D. Immunohistochemical analysis for MVD in HepG2 xenografts and combination therapy enhanced the inhibition of tumor angiogenesis in vivo. Magnification, 200×. *p < 0.05, vs MSC.sFlt1 plus continuous low-dose doxorubicin group.